PEAT Act of 2026

119th Congress Introduced by Brian Babin and 6 co-sponsors

The bill prohibits classifying a biologic as a biological product solely because it contains a clinically inactive protein component.

Introduced in House

Purpose and intent

The bill amends the Public Health Service Act to clarify and restrict how a biologic product is treated for regulatory purposes when the presence of a protein component is clinically inactive.

Specifically, it aims to prohibit classifying or treating a biologic as a “biological product” solely because it contains a protein that is clinically inactive within the biologic.

The overarching goal appears to ensure that regulatory status and oversight reflect the actual clinical activity of protein components, rather than labeling a biologic a biological product based only on the presence of an inactive protein.

Key provisions and changes

Prohibition on regulatory determination based solely on inactive protein:

A biologic would not be considered a biological product merely because it contains a protein that is clinically inactive.

Clarification of what constitutes “clinical inactivity”:

The bill provides a framework to distinguish active vs. inactive protein components within biologics for purposes of regulatory classification.

Alignment with Public Health Service Act definitions:

The amendment adjusts interpretive language within the Act to ensure consistent application of regulatory categories (biologic vs. non-biologic) when the protein components do not contribute clinical activity.

Administrative and procedural considerations:

The bill may affect inquiries, determinations, or registrations submitted to health agencies by manufacturers about product classification, though specific procedural steps are not detailed in the provided summary.

Who or what would be affected

Biologic manufacturers and sponsors seeking regulatory classification or oversight under the Public Health Service Act.

Federal regulators and agencies responsible for determining whether a product is classified as a “biological product.”

Patients and healthcare providers indirectly affected, insofar as regulatory classification can influence oversight, labeling, manufacturing standards, and post-market requirements.

Procedural and timeline aspects

Status: Introduced in the House on April 30, 2026.

Referral: Referred to the House Committee on Energy and Commerce on the same date.

Sponsors: Co-sponsors Michael Rulli and Diana Harshbarger.

No specific enactment timeline or transition period is provided in the available information; typical steps would involve committee consideration, potential amendments, floor consideration, and, if passed, movement to the Senate and further legislative process.

Practical impact and considerations

If enacted, the bill could reduce the likelihood that a biologic product is reclassified or regulated as a biological product solely due to the presence of an inactive protein component.

This may affect regulatory burden, labeling, manufacturing standards, and post-market requirements for certain products, by ensuring inactive components do not drive regulatory categorization.

The precise regulatory, labeling, and enforcement implications would depend on accompanying regulatory guidance and how agencies implement the amended language.

Note: The summary above is based on the bill’s title and available action history. For a complete understanding, reading the full text of HR 8630 and any floor amendments or committee reports would provide detailed definitions, definitions of “clinically inactive,” and the exact regulatory implications.

Bill